FCGR2A

Across TCGA pan-cancer cohorts, FCGR2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FCGR2A data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FCGR2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FCGR2A expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where FCGR2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.215	0.605	<.001	21	view →
HNSC	DFS	Median	II,III,IV	0.899	0.988	.002	15	view →
LUAD	OS	Quartile	II,III,IV	0.353	0.900	.011	8	view →
LSCC	DFS	Median	All	0.898	0.980	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FCGR2A–PDAC (DFS)

Open the PDAC breakdown →